Fluvastatin | CAS#93957-54-1 | statin

MedKoo Cat#: 317900 | Name: Fluvastatin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fluvastatin is a synthetic, fully fluorinated HMG-CoA reductase inhibitor that competitively blocks the rate-limiting step in hepatic cholesterol biosynthesis. By inhibiting conversion of HMG-CoA to mevalonate, it upregulates LDL receptor expression, enhancing clearance of circulating low-density lipoprotein cholesterol. Fluvastatin exhibits high hepatoselectivity, moderate plasma half-life, and a relatively lower risk of myopathy compared to more lipophilic statins.

Chemical Structure

Fluvastatin

CAS#93957-54-1 (free acid)

Theoretical Analysis

MedKoo Cat#: 317900

Name: Fluvastatin

CAS#: 93957-54-1 (free acid)

Chemical Formula: C24H26FNO4

Exact Mass: 411.1846

Molecular Weight: 411.47

Elemental Analysis: C, 70.06; H, 6.37; F, 4.62; N, 3.40; O, 15.55

Price and Availability

Size	Price	Availability
10mg	USD 250.00	2 Weeks
25mg	USD 450.00	2 Weeks
50mg	USD 850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

93957-55-2 (sodium) 94061-81-1 (sodium) 93957-54-1 (free acid) 500103-16-2 (calcium) 1009811-63-5 (potassium)

Synonym

Fluvastatin, Lescol, Canef, Vastin, Cranoc, XU-62320

IUPAC/Chemical Name

(E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid

InChi Key

FJLGEFLZQAZZCD-MCBHFWOFSA-N

InChi Code

InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1

SMILES Code

O=C(O)C[C@H](O)C[C@H](O)/C=C/C(N1C(C)C)=C(C2=CC=C(F)C=C2)C3=C1C=CC=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 411.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Janić M, Lunder M, Šabovič M. A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age. Biomed Res Int. 2015;2015:235709. doi: 10.1155/2015/235709. Epub 2015 Mar 3. Review. PubMed PMID: 25821790; PubMed Central PMCID: PMC4363554. 2: Voûte MT, Winkel TA, Poldermans D. Safety of fluvastatin in patients undergoing high-risk non-cardiac surgery. Expert Opin Drug Saf. 2010 Sep;9(5):793-800. doi: 10.1517/14740338.2010.499120. Review. PubMed PMID: 20557267. 3: Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet. 2008;47(7):463-74. Review. PubMed PMID: 18563955. 4: Stein EA, Corsini A, Gimpelewicz CR, Bortolini M, Gil M. Fluvastatin treatment is not associated with an increased incidence of cancer. Int J Clin Pract. 2006 Sep;60(9):1028-34. Review. PubMed PMID: 16939542. 5: Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol. 2007 Apr 12;117(1):64-74. Epub 2006 Aug 4. Review. PubMed PMID: 16889855. 6: Chan MY, Lee CH. Fluvastatin: efficacy and safety in reducing cardiac events. Expert Opin Pharmacother. 2005 Sep;6(11):1883-95. Review. PubMed PMID: 16144508. 7: Corsini A, Holdaas H. Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Ren Fail. 2005;27(3):259-73. Review. PubMed PMID: 15957541. 8: Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, Wierzbicki AS, Elisaf MS. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin. 2005 Feb;21(2):231-44. Review. PubMed PMID: 15801994. 9: Corsini A. The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin. Int J Clin Pract. 2004 May;58(5):494-503. Review. PubMed PMID: 15206507. 10: Corsini A, Jacobson TA, Ballantyne CM. Fluvastatin: clinical and safety profile. Drugs. 2004;64(12):1305-23. Review. PubMed PMID: 15200346. 11: Tysk C, Al-Eryani AY, Shawabkeh AA. Acute pancreatitis induced by fluvastatin therapy. J Clin Gastroenterol. 2002 Nov-Dec;35(5):406-8. Review. PubMed PMID: 12394230. 12: Langtry HD, Markham A. Fluvastatin: a review of its use in lipid disorders. Drugs. 1999 Apr;57(4):583-606. Review. Erratum in: Drugs 1999 Sep;58(3):404. PubMed PMID: 10235694. 13: Garnett WR. A review of current clinical findings with fluvastatin. Am J Cardiol. 1996 Sep 26;78(6A):20-5. Review. PubMed PMID: 8875971. 14: Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs. 1996 Mar;51(3):433-59. Review. PubMed PMID: 8882381. 15: Peters TK. Treatment of dyslipidaemias with fluvastatin. Br J Clin Pract Suppl. 1996 Jan;77A:16-9. Review. PubMed PMID: 8729585. 16: Baggio G. [An update on the use of fluvastatin in primary hypercholesterolemia]. Ann Ital Med Int. 1995 Oct;10 Suppl:43S. Review. Italian. PubMed PMID: 8562264. 17: Jokubaitis LA. Updated clinical safety experience with fluvastatin. Am J Cardiol. 1994 May 26;73(14):18D-24D. Review. PubMed PMID: 8198019. 18: Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation. 1993 Apr;87(4 Suppl):III45-53. Review. PubMed PMID: 8462180. 19: McDonald KJ, Jardine AG. The use of fluvastatin in cardiovascular risk management. Expert Opin Pharmacother. 2008 Jun;9(8):1407-14. doi: 10.1517/14656566.9.8.1407 . Review. PubMed PMID: 18473714. 20: Asberg A, Holdaas H. Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Rev Cardiovasc Ther. 2004 Sep;2(5):641-52. Review. PubMed PMID: 15350166.